Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 21, Issue 8, 2006, Pages 1281-1285

  Nakamura, Shinichiro ^a   Nouso, Kazuhiro ^a   Noguchi, Yuji ^a   Higashi, Toshihiro ^b   Ono, Toshiro ^a   Jungbluth, Achim ^c   Chen, Yao Tseng ^c   Old, Lloyd J ^c   Nakayama, Eiichi ^a   Shiratori, Yasushi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b Okayama Citizens Hospital   (Japan)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer testis antigens; Human; Immunotherapy; Liver; Neoplasm

Indexed keywords

MESSENGER RNA; NY ESO 1 ANTIGEN; RECOMBINANT PROTEIN;

ADULT; AGED; ANTIBODY DETECTION; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CHRONIC HEPATITIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; PORTAL VEIN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE SECTION;

EID: 33745839341     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04271.x     Document Type: Article

References (16)

1. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 2001; 33: 62-5.
2. Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am. J. Public Health 2000; 90: 1562-9.
3. Boon T, Old LJ. Cancer tumor antigens. Curr. Opin. Immunol. 1997; 9: 681-3.
4. Old LJ, Chen YT. New paths in human cancer serology. J. Exp. Med. 1998; 187: 1163-7.
5. Stockert E, Jager E, Chen YT et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 1998; 187: 1349-54.
6. Jager E, Nagata Y, Gnjatic S et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc. Natl. Acad. Sci. USA 2000; 97: 4760-5.
7. Chen YT, Scanlan MJ, Sahin U et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl Acad. Sci. USA 1997; 94: 1914-18.
8. Sahin U, Koslowski M, Tureci O et al. Expression of cancer testis genes in human brain tumors. Clin. Cancer Res. 2000; 6: 3916-22.
9. Kurashige T, Noguchi Y, Saika T et al. NY-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer Res. 2001; 61: 4671-4.
10. Jungbluth AA, Antonescu CR, Busam KJ et al. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7. Int. J. Cancer 2001; 94: 252-6.
11. Liver Cancer Study Group of Japan. The general rules for the clinical and pathological study of primary liver cancer. Jpn J. Surg. 1989; 19: 98-129.
12. Sobin LH, Wittekind C. TNM Classification of Malignant Tumours, 6th edn. New York: John Wiley & Sons, 2002.
13. Jungbluth AA, Chen YT, Stockert E et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int. J. Cancer 2001; 92: 856-60.
14. Okuda H, Nakanishi T, Takatsu K et al. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer 2000; 88: 544-9.
15. Koike Y, Shiratori Y, Sato S et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001; 91: 561-9.
16. Gnjatic S, Nagata Y, Jager E et al. Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc. Natl Acad. Sci. USA 2000; 97: 10917-22.